Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760473 · ClinicalTrials.gov registry record · Phase 3
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
A Phase 3 study of Heroin Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT01760473 is a Phase 3 study of Heroin Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 27 participants, below the 106-participant average among 8 other Heroin Dependence trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01760473, a Phase 3 study of Heroin Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. The investigators hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine alone.
Conditions Studied
Interventions
- DRUG Intranasal challenge drug
Study Locations (1)
New York
- New York State Psychiatric Institute and Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01760473
The ClinicalTrials.gov registry entry for NCT01760473 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 8 other Heroin Dependence trials with a reported enrollment target (75% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heroin Dependence appearing as the primary indexed condition, and to 1 intervention - of which Intranasal challenge drug is the first listed.
NCT01760473 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01760473 about?
NCT01760473 is a clinical study titled "Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone". The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. The investigators hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine ...
What is the current status of trial NCT01760473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2009-05. Estimated completion is 2014-12.
What conditions does trial NCT01760473 study?
This clinical trial studies the following conditions: Heroin Dependence.
What interventions are being tested in trial NCT01760473?
The interventions under investigation include: Intranasal challenge drug (DRUG).
Who is sponsoring clinical trial NCT01760473?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01760473 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heroin Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
COMPLETED · Phase 3
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
COMPLETED · Phase 3
-
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
COMPLETED · Phase 3
-
Directly Administered HIV Therapy in Methadone Clinics
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.